Skip to content
Loading...
Media
Careers
Contact
en
sv
Search
Search for:
Search
Search
Search for:
Search
en
sv
Menu
en
sv
About Us
About Us
Management Team
Board of Directors
Our History
Grants
Our Science
Our Science
Pipeline
NOX Enzyme Inhibitors
Setanaxib
Primary Biliary Cholangitis (PBC)
Idiopathic Pulmonary Fibrosis (IPF)
Alport Syndrome
Solid Tumors
Presentations & Publications
Our Products
Partnerships
Patients
Patients
Managing igA Nephropathy
Current Clinical Trials
Expanding Access to TARPEYO
Investors
Investors
Invest in Calliditas
Sustainability
The Share
Trading Information
Ownership Structure
Share Capital Development
Dividend Policy
Analyst Coverage
Financial Reports and Presentations
SEC Filings
Press Releases
Calliditas in media
Calendar
Investor FAQs
Contact
Governance
Governance
Corporate Governance Reports
General Meeting
Annual general meeting 2024
General Meetings
Nomination Committee
Nomination Committees
Board and Committees
Board of Directors
Board Fees
Work of the Board of Directors
Committees
Management
Management Team
Remuneration
Internal Control & Risk Management
Auditor
Articles of Association
Media
Careers
Contact
Financial Reports and Presentations
2021
All years
2024
2023
2022
2021
2020
2019
2018
2017
Type of information
All types
Annual reports
Company presentations
Interim reports
Webinars
Report
Presentation
Webcast
December 16, 2021
FDA Approval – Investor Update
November 18, 2021
Interim Report Q3 2021
August 19, 2021
Interim Report Q2 2021
May 18, 2021
Interim Report Q1 2021
April 27, 2021
Annual Report 2020
March 10, 2021
KOL Perspectives: The Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice
February 18, 2021
Year-end report 2020
